Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM2C1YN)

Drug Name
MEGF0444A Drug Info
Indication
Disease Entry ICD 11 Status REF
Metastatic colorectal cancer 2B91 Phase 2 [1]
Non-small-cell lung cancer 2C25.Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM2C1YN

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor-like protein 7 (EGFL7) TT7WD0H EGFL7_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Epidermal growth factor-like protein 7 (EGFL7) DTT EGFL7 6.632 5.514 4.907 6.053
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Metastatic colorectal cancer
ICD Disease Classification 2B91
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor-like protein 7 (EGFL7) DTT EGFL7 2.56E-01 0.07 0.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2 A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614.